An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Chronic kidney disease patients on hemodialysis or hemodiafiltration for at least 3 months
Previously treated with an erythropoietin stimulating agent (ESA)
Patient for whom the investigator decided to initiate treatment with Mircera for medical reasons
Last hemoglobin level before initiation of Mircera within the range of 10-12 g/dL
You may not be if
Current participation in a clinical trial on renal anemia
Clareo Health | An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)
